The diagnosis of Parkinson's disease

Lancet Neurology

Volumn 5, Issue 1, 2006, Pages 75-86

  Tolosa, Eduardo ^a   Wenning, Gregor ^b   Poewe, Werner ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BUTYROPHENONE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; RISPERIDONE; TETRABENAZINE; VALPROIC ACID;

ALZHEIMER DISEASE; ATROPHY; CORTICOBASAL DEGENERATION; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; ECHOGRAPHY; ELECTRONEUROLOGY; ESSENTIAL TREMOR; GENETIC ANALYSIS; HUMAN; LEWY BODY; MOTOR DYSFUNCTION; MULTISYSTEM ATROPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMELLING; VASCULAR PARKINSONISM;

DIAGNOSIS, DIFFERENTIAL; HUMANS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY;

EID: 29044435205     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(05)70285-4     Document Type: Review

References (164)

1. DJ Gelb, E Oliver, S Gilman Diagnostic criteria for Parkinson disease Arch Neurol 56 1999 33 39
2. WR Gibb, AJ Lees The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease J Neurol Neurosurg Psychiatry 51 1988 745 752
3. AJ Hughes, SE Daniel, L Kilford, AJ Lees Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 55 1992 181 184
4. AH Rajput, B Rozdilsky, A Rajput Accuracy of clinical diagnosis in Parkinsonism: a prospective study Can J Neurol Sci 18 1991 275 278
5. J Jankovic, AH Rajput, MP McDermott, DP Perl The evolution of diagnosis in early Parkinson disease Arch Neurol 57 2000 369 372
6. AJ Hughes, SE Daniel, AJ Lees Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease Neurology 57 2001 1497 1499
7. AJ Hughes, SE Daniel, Y Ben-Shlomo, AJ Lees The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service Brain 125 part 4 2002 861 870
8. Y Osaki, GK Wenning, SE Daniel Do published criteria improve clinical diagnostic accuracy in multiple system atrophy? Neurology 59 2002 1486 1491
9. Y Osaki, Y Ben-Shlomo, AJ Lees Accuracy of clinical diagnosis of progressive supranuclear palsy Mov Disord 19 2004 181 189
10. A Schrag, Y Ben-Shlomo, N Quinn How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry 73 2002 529 534
11. J Meara, BK Bhowmick, P Hobson Accuracy of diagnosis in patients with presumed Parkinson's disease Age Ageing 28 1999 99 102
12. M Emre Dementia associated with Parkinson's disease Lancet Neurol 2 2003 229 237
13. I McKeith, J Mintzer, D Aarsland Dementia with Lewy bodies Lancet Neurol 3 2004 19 28
14. G Deuschl, PG Bain, M Brin Consensus statement of the Movement Disorder Society on tremor Mov Disord 13 1998 2 23
15. ED Louis, G Levy, LJ Cote, H Mejia, S Fahn, K Marder Clinical correlates of action tremor in Parkinson disease Arch Neurol 58 2001 1630 1634
16. J Jankovic, KS Schwartz, W Ondo Re-emergent tremor of Parkinson's disease J Neurol Neurosurg Psychiatry 67 1999 646 650
17. O Cohen, S Pullman, E Jurewicz, D Watner, ED Louis Rest tremor in patients with essential tremor: prevalence, clinical correlates, and electrophysiologic characteristics Arch Neurol 60 2003 405 410
18. KR Chaudhuri, M Buxton-Thomas, V Dhawan, R Peng, C Meilak, DJ Brooks Long duration asymmetrical postural tremor is likely to predict development of Parkinson's disease and not essential tremor: clinical follow up study of 13 cases J Neurol Neurosurg Psychiatry 76 2005 115 117
19. ED Louis, B Ford, KJ Wendt, G Cameron Clinical characteristics of essential tremor: data from a community based study Mov Disord 13 1998 803 808
20. M Ghaemi, J Raethjen, R Hilker Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study Mov Disord 17 2002 782 788
21. M Critchley Arteriosclerotic parkinsonism Brain 52 1929 23 83
22. JC Zijlmans, SE Daniel, AJ Hughes, T Revesz, AJ Lees Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis Mov Disord 19 2004 630 640
23. I Reider-Groswasser, NM Bornstein, AD Korczyn Parkinsonism in patients with lacunar infarcts of the basal ganglia Eur Neurol 35 1995 46 49
24. C Peralta, P Werner, B Holl Parkinsonism following striatal infarcts: incidence in a prospective stroke unit cohort J Neural Transm 111 2004 1473 1483
25. AJ Hughes, SE Daniel, L Kilford, AJ Lees The accuracy of the clinical diagnosis of Parkinson disease: a clinicopathological study of 100 cases J Neurol Neurosurg Psychiatry 55 1992 181 184
26. PM FitzGerald, J Jankovic Lower body parkinsonism: evidence for vascular etiology Mov Disord 4 1989 249 260
27. M Van Zagten, J Lodder, F Kessels Gait disorder and parkinsonian signs in patients with stroke related to small deep infarcts and white matter lesions Mov Disord 13 1998 89 95
28. PD Thompson, CD Marsden Gait disorder of subcortical arteriosclerotic encephalopathy: Binswanger's disease Mov Disord 2 1987 1 8
29. E Tolosa, J Santamaria Parkinsonism and basal ganglia infarcts Neurology 34 1984 1516 1518
30. J Winikates, J Jankovic Clinical correlates of vascular parkinsonism Arch Neurol 56 1999 98 102
31. F Tison, B Duche, P Loiseau Syndrome hémiparkinsonien vasculaire Rev Neurol (Paris) 149 1993 565 567
32. JC Zijlmans, HO Thijssen, OJ Vogels MRI in patients with suspected vascular parkinsonism Neurology 45 1995 2183 2188
33. R Katzenschlager, J Zijlmans, A Evans, H Watt, AJ Lees Olfactory function distinguishes vascular parkinsonism from Parkinson's disease J Neurol Neurosurg Psychiatry 75 2004 1749 1752
34. IG McKeith, D Galasko, K Kosaka Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop Neurology 47 1996 1113 1124
35. D Aarsland, K Andersen, JP Larsen, A Lolk, H Nielsen, P Kragh-Sorensen Risk of dementia in Parkinson's disease: a community-based, prospective study Neurology 56 2001 730 736
36. R Mayeux, J Denaro, N Hemenegildo A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender Arch Neurol 49 1992 492 497
37. K Marder, MX Tang, L Cote, Y Stern, R Mayeux The frequency and associated risk factors for dementia in patients with Parkinson's disease Arch Neurol 52 1995 695 701
38. CG Ballard, D Aarsland, I McKeith Fluctuations in attention: PD dementia vs DLB with parkinsonism Neurology 59 2002 1714 1720
39. I McKeith, A Fairbairn, R Perry, P Thompson, E Perry Neuroleptic sensitivity in patients with senile dementia of Lewy body type BMJ 305 1992 673 678
40. AJ Harding, GA Broe, GM Halliday Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe Brain 125 2002 391 403
41. P Ibanez, AM Bonnet, B Debarges Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease Lancet 364 2004 1169 1171
42. MC Chartier-Harlin, J Kachergus, C Roumier α-synuclein locus duplication as a cause of familial Parkinson's disease Lancet 364 2004 1167 1169
43. AB Singleton, M Farrer, J Johnson Alpha-Synuclein locus triplication causes Parkinson's disease Science 302 2003 841
44. JJ Zarranz, J Alegre, JC Gómez-Esteban The new mutation, E46K, of α-synuclein causes parkinson and Lewy body dementia Ann Neurol 55 2004 164 173
45. JC Steele, JC Richardson, J Olszewski Progressive supranuclear palsy: a heterogeneous degeneration involving the brainstem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia Arch Neurol 10 1964 333 359
46. I Litvan, Y Agid, D Calne Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop Neurology 47 1996 1 9
47. E Tolosa, F Vallderiola, F Cruz-Sanchez Progressive supranuclear palsy: clinical and pathological diagnosis Eur J Neurol 2 1995 259 273
48. SE Daniel, VM de Bruin, AJ Lees The clinical and pathological spectrum of Steel-Richardson-Olszewski syndrome - progressive supranuclear palsy: a reappraisal Brain 118 1995 759 770
49. U Nath, Y Ben-Shlomo, RG Thomson The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK Brain 124 2001 1438 1449
50. SJ Collins, JE Ahlskog, JE Parisi, DM Maraganore Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria J Neurol Neurosurg Psychiatry 58 1995 167 173
51. I Litvan Update on epidemiological aspects of progressive supranuclear palsy Mov Disord 18 suppl 6 2003 S43 S50
52. JG De Yébenes, JL Sarasa, SE Daniel, AJ Lees Familial progressive supranuclear palsy: description of a pedigree and review of the literature Brain 118 part 5 1995 1094 1103
53. KA Nieforth, LI Golbe Retrospective study of drug response in 87 patients with progressive supranuclear palsy Clin Neuropharmacol 16 1993 338 346
54. DR Williams, R de Silva, DC Paviour Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism Brain 128 part 6 2005 1247 1258
55. J-J Hauw, SE Daniel, D Dickson Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy) Neurology 44 1994 2015 2019
56. PL Lantos The definition of multiple system atrophy: a review of recent developments J Neuropathol Exp Neurol 57 1998 1099 1111
57. GK Wenning, Y Ben Shlomo, M Magalhaes, SE Daniel, NP Quinn Clinical features and natural history of multiple system atrophy: an analysis of 100 cases Brain 117 part 4 1994 835 845
58. S Gilman, PA Low, N Quinn Consensus statement on the diagnosis of multiple system atrophy J Auton Nerv Syst 74 1998 189 192
59. C Colosimo, A Albanese, AJ Hughes, VM de Bruin, AJ Lees Some specific features differentiate multiple system atrophy (striatonigral degeneration) for Parkinson's disease Arch Neurol 52 1995 294 298
60. N Gouider-Khouja, M Vidailhet, AM Bonnet, J Pichon, I Agid Pure striatonigral degeneration and Parkinson disease: a comparative clinical study Mov Disord 10 1995 288 294
61. AJ Hughes, C Colosimo, B Kleedorfer, SE Daniel, AJ Lees The dopaminergic response in multiple system atrophy J Neurol Neurosurg Psychiatry 55 1992 1009 1013
62. R Kumar, C Bergeron, A Lang Cortical basal degeneration J Jankovic E Tolosa Parkinson's disease and movement disorders 2002 Lippincott Williams and Wilkins 185 198
63. PA Hanna, RS Doody Alien limb sign Adv Neurol 82 2000 135 145
64. JO Rinne, MS Lee, PD Thompson, CD Marsden Corticobasal degeneration: a clinical study of 36 cases Brain 117 part 5 1994 1183 1196
65. DA Grimes, AE Lang, CB Bergeron Dementia is the most common presentation of cortical-basal ganglionic degeneration Neurology 53 1999 1969 1974
66. K Kompoliti, CG Goetz, BF Boeve Clinical presentation and pharmacological therapy in corticobasal degeneration Arch Neurol 55 1998 957 961
67. FJ Jiménez-Jiménez, M Ortí-Pareja, L Ayuso-Peralta Drug-induced parkinsonism in a movement disorder unit: a four-year survey Parkinsonism Rel Disord 2 1996 145 149
68. RJ Hardie, AJ Lees Neuroleptic-induced parkinson's syndrome: clinical features and results of treatment with levodopa J Neurol Neurosurg Psychiatry 51 1988 850 854
69. J Jankovic, J Casabona Coexistent tardive dyskinesia and parkinsonism Clin Neuropharmacol 10 1987 511 521
70. E Tolosa, M Coelho, M Gallardo DAT imaging in drug-induced and psychogenic parkinsonism Mov Disord 18 suppl 7 2003 S28 S33
71. G Wenning, Y Ben-Shlomo, A Hughes, SE Daniel, AJ Lees, NP Quinn What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry 68 2000 434 440
72. G Wenning, K Seppi, K Jellinger Survival of patients of dementia with Lewy bodies: a metaanalysis of 236 post-mortem confirmed cases Neurology 54 suppl 3 2000 391 392
73. GK Wenning, Y Ben-Shlomo, M Magalhaes, NP Quinn Clinicopathological study of 35 cases of multiple system atrophy J Neurol Neurosurg Psychiatry 58 1995 160 166
74. I Litvan, CA Mangone, A McKee Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study J Neurol Neurosurg Psychiatry 60 1996 615 620
75. GK Wenning, I Litvan, J Jankovic Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination J Neurol Neurosurg Psychiatry 64 1998 184 189
76. V Bonifati, BA Oostra, P Heutink Unraveling the pathogenesis of Parkinson's disease: the contribution of monogenic forms Cell Mol Life Sci 61 2004 1729 1750
77. CB Lücking, A Durr, V Bonifati Association between early-onset Parkinson's disease and mutations in the parkin gene N Engl J Med 342 2000 1560 1567
78. J Johnson, SM Hague, M Hanson SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies Neurology 63 2004 554 556
79. C Paisan-Ruiz, S Jain, EW Evans Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease Neuron 44 2004 595 600
80. A Zimprich, S Biskup, P Leitner Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology Neuron 44 2004 601 607
81. WC Nichols, N Pankratz, D Hernandez Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease Lancet 365 2005 410 412
82. A Di Fonzo, CF Rohe, J Ferreira Italian Parkinson Genetics Network: a frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease Lancet 365 2005 412 415
83. WP Gilks, PM Abou-Sleiman, S Gandhi A common LRRK2 mutation in idiopathic Parkinson's disease Lancet 365 2005 415 416
84. R Barker, J Duncan, A Lees Subcutaneous apomorphine as a diagnostic test for dopaminergic responsiveness in parkinsonian syndromes Lancet 333 1989 675
85. WH Oertel, T Gasser, R Ippisch Apomorphine test for dopaminergic responsiveness Lancet 333 1989 1262 1263
86. AJ Hughes, AJ Lees, GM Stern Apomorphine test to predict dopamingergic responsiveness in parkinsonian syndromes Lancet 336 1990 32 34
87. T Gasser, J Schwarz, G Arnold, C Trenkwalder, WH Oertel Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease Arch Neurol 49 1992 1131 1134
88. AJ Hughes, AJ Lees, GM Stern Challenge tests to predict the dopaminergic response in untreated Parkinson's disease Neurology 41 1991 1723 1725
89. M Merello, MI Nouzeilles, GP Arce, R Leiguarda Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis Mov Disord 17 2002 795 798
90. C Colosimo, FR Pezzella The symptomatic treatment of multiple system atrophy Eur J Neurol 9 2002 195 199
91. J Zijlmans, R Katzenschlager, SE Daniel, AJ Lees The L-dopa response in vascular parkinsonism J Neurol Neurosurg Psychiatry 75 2004 545 547
92. CE Clarke, P Davies Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease J Neurol Neurosurg Psychiatry 69 2000 590 594
93. R Benecke, JP Dick, JC Rothwell, BL Day, CD Marsden Increase of the Bereitschaftspotential in simultaneous and sequential movements Neurosci Lett 62 1985 347 352
94. L Deecke Clinical neurophysiology of Parkinson's disease: bereitschaftspotential and contingent negative variation Adv Neurol 86 2001 257 271
95. WG Tatton, RG Lee Evidence for abnormal long-loop reflexes in rigid parkinsonian patients Brain Res 100 1975 671 676
96. R Bordet, J Benhadjali, A Destee, JF Hurtevent, JL Bourriez, JD Guieu Sympathetic skin response and RR interval variability in multiple system atrophy and idiopathic Parkinson's disease Mov Disord 11 1996 268 272
97. M Kofler, J Müller, GK Wenning The auditory startle reaction in parkinsonian disorders Mov Disord 16 2001 62 71
98. I Eardley, NP Quinn, CJ Fowler The value of urethral spincter electromyography in the differential diagnosis of parkinsonism Br J Urol 64 1989 360 362
99. F Valldeoriola, J Valls-Sole, ES Tolosa, MJ Marti Striated anal sphincter denervation in patients with progressive supranuclear palsy Mov Disord 10 1995 550 555
100. PD Thompson, BL Day, JC Rothwell, P Brown, TC Britton, CD Marsden The myoclonus in corticobasal degeneration: evidence for two forms of cortical reflex myoclonus Brain 117 part 5 1994 1197 1207
101. M Vidailhet, S Rivaud, N Gouider-Khouja Eye movements in parkinsonian syndromes Ann Neurol 35 1994 420 426
102. GK Wenning, K Seppi, W Poewe, NP Quinn, CJ Mathias Differential association of orthostatic hypotension with the cerebellar versus parkinsonian presentation of multiple system atrophy. 53rd Annual Meeting of the AAN Neurology 56 2001 444
103. GK Wenning, C Scherfler, R Granata Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study J Neurol Neurosurg Psychiatry 67 1999 620 623
104. AM Bonnet, J Pichon, M Vidailhet Urinary disturbances in striatonigral degeneration and Parkinson's disease: clinical and urodynamic aspects Mov Disord 12 1997 509 513
105. DE Riley, TC Chelimsky Autonomic nervous system testing may not distinguish multiple system atrophy from parkinson's disease J Neurol Neurosurg Psychiatry 74 2003 56 60
106. J Kimber, CJ Mathias, AJ Lees Physiological, pharmacological and neurohormonal assessment of autonomic function in progressive supranuclear palsy Brain 123 part 7 2000 1422 1430
107. R Katzenschlager, AJ Lees Olfaction and Parkinson's syndromes: its role in differential diagnosis Curr Opin Neurol 17 2004 417 423
108. GK Wenning, B Shephard, C Hawkes, A Petruckevitch, A Lees, N Quinn Olfactory function in atypical parkinsonian syndromes Acta Neurol Scand 91 1995 247 250
109. NL Khan, R Katzenschlager, H Watt Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease Neurology 62 2004 1224 1226
110. MM Ponsen, D Stoffers, J Booij, BL van Eck-Smit, ECh Wolters, HW Berendse Idiopathic hyposmia as a preclinical sign of Parkinson's disease Ann Neurol 56 2004 173 181
111. A Muller, H Reichmann, A Livermore, T Hummel Olfactory function in idiopathic Parkinson's disease: results from cross-sectional studies in IPD patients and long-term follow-up of de novo IPD patients J Neural Transm 109 2002 805 811
112. R Inzelberg, NM Bornstein, I Reider, AD Korczyn Basal ganglia lacunes and parkinsonism Neuroepidemiol 13 1994 108 112
113. B Drayer, W Olanow, P Burger, GA Johnson, R Herfkens, S Riederer Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron Radiology 159 1986 493 498
114. A Schrag, CD Good, K Miszkiel Differentiation of atypical parkinsonian syndromes with routine MRI Neurology 54 2000 697 702
115. M Warmuth-Metz, M Naumann, I Csoti, L Solymosi Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy Arch Neurol 58 2001 1076 1079
116. P Soliveri, D Monza, D Paridi Cognitive and magnetic resonance imaging aspects of corticobasal degeneration and progressive supranuclear palsy Neurology 53 1999 502 507
117. K Bhattacharya, D Saadia, B Eisenkraft Brain magnetic resonance imaging in multiple-system atrophy and Parkinson disease: a diagnostic algorithm Arch Neurol 59 2002 835 842
118. E Kraft, J Schwarz, C Trenkwalder, T Vogl, T Pfluger, WH Oertel The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy? Arch Neurol 56 1999 225 228
119. E Kraft, C Trenkwalder, DP Auer T2-weighted MRI differentiates multiple system atrophy from Parkinson's disease Neurology 59 2002 1265 1267
120. A Righini, A Antonini, M Ferrarini Thin section MR study of the basal ganglia in the differential diagnosis between striatonigral degeneration and Parkinson disease J Comput Assist Tomogr 26 2002 266 271
121. J Schulz, M Skalej, D Wedekind Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy Ann Neurol 45 1999 65 74
122. CA Davie, GK Wenning, GJ Barker Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy Ann Neurol 37 1995 204 210
123. CE Clarke, M Lowry Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes Eur J Neurol 8 2001 573 577
124. F Federico, IL Simone, V Lucivero Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders Mov Disord 12 1997 903 909
125. M Schocke, K Seppi, R Esterhammer Diffusion weighted MRI differentiates the Parinson variant of multiple system atrophy from PD Neurology 58 2002 575 580
126. K Seppi, MF Schocke, R Esterhammer Diffusion weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy Neurology 60 2003 922 927
127. T Brücke, S Wenger, S Asenbaum Dopamine D2 receptor imaging and measurement with SPECT Adv Neurol 60 1993 494 500
128. J Schwarz, K Tatsch, G Arnold [123-I]-iodobenzamide-SPECT in 83 patients with de novo parkinsonism Neurology 43 suppl 6 1993 S17 S20
129. J Schwarz, K Tatsch, T Gasser [123-I]-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism Mov Disord 13 1998 16 19
130. L Schelosky, J Hierholzer, J Wissel, M Cordes, W Poewe Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by [123-I]-IBZM-SPECT Mov Disord 8 1993 453 458
131. K Seppi, MF Schocke, E Donnemiller Comparison of DWI and [123-I]-IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from PD Mov Disord 19 2004 1438 1445
132. KL Marek, JP Seibyl, SS Zoghbi [123-I]-β-CIT-SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease Neurology 46 1996 231 237
133. GK Wenning, E Donnemiller, R Granata, G Riccabona, W Poewe [123-I]-beta-CIT and [123-I]-IBZM-SPECT scanning in levodopa-naive Parkinson's disease Mov Disord 13 1998 438 445
134. HT Benamer, WH Oertel, J Patterson Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations Mov Disord 18 2003 977 984
135. J Booij, JD Speelman, MWIM Horstink, EC Wolters The clinical benefit of imaging striatal dopamine transporters with [123 I] FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism Eur J Nucl Med 28 2001 266 272
136. TS Benamer, J Patterson, DG Grosset Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]FP-CIT SPECT imaging: the [123I]FP-CIT study group Mov Disord 15 2000 503 510
137. W Gerschlager, G Bencsits, W Pirker [123I]b-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease Mov Disord 17 2002 518 523
138. W Poewe, C Scherfler Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice Mov Disord 18 suppl 7 2003 S16 S21
139. AM Catafau, E Tolosa DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes Mov Disord 19 2004 1175 1182
140. K Marek, R Innis, C van Dyck [123I]b-CIT SPECT imaging assessment of the rate of Parkinson's disease progression Neurology 57 2001 2089 2094
141. Parkinson Study Group Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson's disease progression JAMA 287 2002 1653 1661
142. W Pirker, S Djamshidian, S Asenbaum Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal b-CIT SPECT study Mov Disord 17 2002 45 53
143. C Scherfler, K Seppi, E Donnemiller Voxel-wise analysis of [123I]{beta}-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease Brain 128 part 7 2005 1605 1612
144. S Braune, M Reinhardt, R Schnitzer, A Riedel, CH Lücking Cardiac uptake of [123-I])-MIBG separates Parkinson's disease from multiple system atrophy Neurology 53 1999 1020 1025
145. M Yoshita Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy J Neurol Sci 155 1998 60 67
146. S Braune The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes Clin Auton Res 11 2001 351 355
147. F Courbon, C Brefel-Courbon, C Thalamas Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease Mov Disord 18 2003 890 897
148. PK Morrish, GV Sawle, DJ Brooks An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease Brain 199 part 2 1996 585 591
149. E Nurmi, HM Ruottinen, J Bergman Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study Mov Disord 16 2001 608 615
150. AL Whone, RL Watts, AJ Stoessl Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study Ann Neurol 54 2003 93 101
151. PK Morrish, GV Sawle, DJ Brooks Clinical and [18F]dopa PET findings in early Parkinson's disease J Neurol Neurosurg Psychiatry 59 1995 597 600
152. P Piccini, DJ Burn, R Ceravolo, D Maraganore, DJ Brooks The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins Ann Neurol 45 1999 577 582
153. D Brooks, V Ibanez, GV Sawle Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy Ann Neurol 28 1990 547 555
154. DJ Burn, GV Sawle, DJ Brooks Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data J Neurol Neurosurg Psychiatry 57 1994 278 284
155. DJ Brooks, V Ibanez, GV Sawle Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography Ann Neurol 31 1992 184 192
156. D Eidelberg, JR Moeller, T Ishikawa Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography Neurology 45 1995 1995 2004
157. A Antonini, K Kazamuta, A Feigin Differential diagnosis of parkinsonism with 18F-fluorodeoxyglucose and PET Mov Disord 13 1998 268 274
158. D Berg, G Becker Perspectives of B-mode transcranial ultrasound Neuroimage 15 2002 463 473
159. G Becker, J Seufert, U Bogdahn, H Reichmann, K Reiners Degeneration of substantia nigra in chronic Parkinson's disease visualised by transcranial color-coded real-time sonography Neurology 45 1995 182 184
160. D Berg, C Siefker, G Becker Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings J Neurol 248 2001 684 689
161. U Walter, M Wittstock, R Benecke, D Dressler Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease J Neural Transm 109 2002 191 196
162. D Berg, W Roggendorf, U Schröder Echogenicity of the substantia nigra - association with increased iron content and marker for susceptibility to nigrostriatal injury Arch Neurol 59 2002 999 1005
163. P Ruprecht-Dörfler, D Berg, O Tucha Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease Neuroimage 18 2003 416 422
164. U Walter, L Niehaus, T Probst, R Benecke, BU Meyer, D Dressler Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes Neurology 60 2003 74 77